Wanbury: Press Relea s e regarding filing new Drug Master File (DMF) in South Africa for Tramadol HCI APL
Wanbury (WANBURY) filed a disclosure titled "Press Relea s e regarding filing new Drug Master File (DMF) in South Africa for Tramadol HCI APL". The company is valued at about ₹694 crore.
What happened
Wanbury (WANBURY) filed a disclosure with the exchanges on 8 October 2026 at 01:04 PM titled "Press Relea s e regarding filing new Drug Master File (DMF) in South Africa for Tramadol HCI APL".
Company snapshot
Wanbury is a micro-cap company, with a market value of about ₹694 crore.
The stock last traded at ₹198.5, against a 52-week range of ₹161.5–₹358.9 (44.7% below the high).
Before this filing the shares had moved −21.0% over the month and −30.3% over three months. Average daily turnover over the last 20 sessions was about ₹5.42 crore.
Promoters held 43.02% at the end of Q1 FY27; 86.69% of promoter shares were pledged. Foreign institutions owned 0.89% and domestic institutions 0.06%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 163 | 13.5 | 4.12 |
| Q2 FY26 | 160 | 15.2 | 4.58 |
| Q3 FY26 | 162 | 15.8 | 4.52 |
| Q4 FY26 | 165 | 21.7 | 7.33 |
| Q1 FY27 | 166 | 3.2 | 0.93 |
What history shows
BCEIE has no earlier similar filing from this company on record since May 2026.
Market-wide, 78 similar filings with an impact score of 50 or more saw an average next-day move of +0.5%, with 46% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.